Contract Pharmacal Corp

What Contract Pharmacal Corp does

Contract Pharmacal Corp (CPC) is a privately held, family-owned contract development and manufacturing organization (CDMO) founded in 1971 by John L. Wolf and Harriet L. Wolf, now run by their sons Matthew Wolf (CEO) and Mark Wolf (President). The company develops, manufactures, and packages solid-dose pharmaceuticals (tablets, capsules, pellets, granules, powders, effervescents) and dietary supplements from ten facilities totaling ~1 million square feet in Hauppauge, New York, including 500,000+ square feet of warehousing with 30,000 pallet positions. Annual solid-dose capacity is 25 billion tablets/capsules, 250 million bottles, and 3 billion sachets; the company has commercialized more than 5,000 unique formulas since inception and develops roughly 100 new products per year. Regulatory infrastructure includes cGMP laboratories (HPLC, UPLC, GC, ICP, mass spectrometry, PCR, microbiological testing), expertise in ANDA/NDA/505(b)(2) submissions, FDA registration with no observations across the last eight FDA inspections, DEA Schedule 1-5 registration, TGA, Health Canada FSRN, UL, Organic, Kosher, Halal, and Gluten-Free certifications, and a wholly owned Indian R&D subsidiary (CPC India) providing formulation, analytical, bioequivalence, and technology-transfer services.

CPC operates a B2B contract-manufacturing revenue model, earning quote-based, project-tied fees from formulation development, analytical development, commercial manufacturing, and full-service packaging (bottling, blistering, canisters, folding cartons, physician samples, pouching). The go-to-market motion is enterprise field sales targeting pharmaceutical companies, retailers, and wholesalers through dedicated business development executives. The active customer base exceeds 60 global accounts and includes Bayer, Sanofi, CVS Health, Walgreens, GNC, Vitamin World, Cardinal Health, AmerisourceBergen, Procter & Gamble, and Kenvue. Customer segments are organized vertically: pharmaceutical companies (OTC and solid-dose Rx), retailers (store-brand OTC and supplements), and wholesalers (generic distribution). Pricing is non-public, multi-year, and customized by product complexity, volume, and regulatory scope.

The company has expanded organically via a 2018 Hauppauge facility extension (~140,000 sq ft) supported by Suffolk County IDA tax abatement and New York State ESDC incentives totaling ~$8 million plus 1.3 MW of NYPA ReCharge NY power, and inorganically via a 2019 strategic investment in Florida Pharmaceutical Products, LLC. In 2023 CPC appointed a Chief Strategy Officer (Glenn Langberg) and a VP of Business Development (Larry Lapila, formerly President of Breckenridge Pharmaceutical and Florida Pharmaceutical Products) and launched direct-to-consumer e-commerce for its in-house vitamin and supplement brand, Earth's Splendor. The workforce stands at 1,250-1,400 professionals across the U.S. and India operations.

Name

Contract Pharmacal Corp

Legal name

Contract Pharmacal Corp

Website

https://cpc.com

Company type

Private

Founded year

1971

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Contract Pharmacal Corp is a family-owned, Hauppauge-based CDMO founded in 1971 that develops, manufactures, and packages solid-dose pharmaceuticals and dietary supplements for 60+ global pharmaceutical, retail, and wholesale customers across ten facilities totaling ~1 million square feet.

Ownership category

akta.pro rank

Product category

Contract Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Contract pharmaceutical manufacturing
• Solid dose manufacturing
• Dietary supplement manufacturing
• OTC drug manufacturing
• Pharmaceutical packaging services

Headquarters

HQ city

Hauppauge

HQ country

United States

HQ region

North America

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: CPC generates revenue through contract development and manufacturing fees for solid-dose drugs and dietary supplements. Services include formulation development, analytical development, manufacturing, and packaging. Pricing is quote-based based on product complexity, volume, and specifications.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Contract Pharmacal Corp (CPC) is a full-service contract development and manufacturing organization (CDMO) for the nutraceutical and pharmaceutical industries, developing, manufacturing, and packaging solid-dose OTC drugs, solid-dose Rx pharmaceuticals, and dietary supplements in tablet, capsule, pellet, granule, powder, and effervescent forms. The offering spans formulation R&D, analytical development, regulatory support (ANDA/NDA/505(b)(2)), commercial manufacturing, and full-service packaging (bottling, blistering, canisters, pouches), with an Indian R&D subsidiary (CPC India) supporting technology transfer, bioequivalence and clinical services.

Product overview

Contract Pharmacal Corp (CPC) is a full-service contract development and manufacturing organization (CDMO) for the nutraceutical and pharmaceutical industries. The company offers end-to-end services from concept to commercialization, including formulation research and development, analytical development, regulatory support, and commercial manufacturing of solid-dose pharmaceuticals and dietary supplements. Core products include tablets, capsules, pellets, granules, powders, and effervescents, complemented by full-service packaging solutions (bottling, blistering, canisters, pouching). The company operates a subsidiary R&D center in India providing formulation development, analytical services, technology transfer, and bioequivalence studies. CPC also markets its own in-house vitamin and supplement brand, Earth's Splendor, sold via e-commerce.

Differentiator

Problem solved

Functional benefit

Brands

• Earth's Splendor: In-house vitamin and supplement brand marketed by Contract Pharmacal Corp, which launched its e-commerce website in 2023

Products and services

• Solid-Dose Pharmaceutical Manufacturing Contract manufacturing of solid-dose pharmaceuticals including tablets, bilayered tablets, capsules, banded capsules, pellets, granules, powders, and effervescents for over-the-counter drugs and prescription medications, served to enterprise pharmaceutical customers.
• Dietary Supplement Manufacturing Development and contract manufacturing of dietary supplements including vitamins, minerals, and other nutraceutical products in various solid-dose forms, served to retailers, wholesalers, and pharmaceutical customers.
• Packaging Services Full-service pharmaceutical packaging solutions including bottling, blistering, canisters, folding cartons, physician samples, and tablet/powder pouching using high-speed, fully-automated packaging lines, for OTC, Rx, and supplement customers.
• Formulation Research and Development Product development services using Quality-By-Design tools such as Design of Experiment (DOE) and risk assessment with Critical Quality Attributes (CQA), including prototype formulation development and process optimization, delivered via CPC India to pharma and nutrition customers.
• Analytical Research and Development Analytical method development and validation services including residual solvent analysis, dissolution studies, elemental analysis, particle size analysis, and stability studies as per ICH guidelines, delivered through CPC India.
• Regulatory Services Regulatory support including dossier compilation, FDA submissions (ANDA, NDA, 505(b)(2)), addressing deficiency questions, and product lifecycle management for pharmaceutical and supplement customers.
• Technology Transfer Transfer of methods and technology to global manufacturing sites for scale-up and commercialization of pharmaceutical dosage forms, executed via systematic protocol-based project management.
• Bioequivalence and Clinical Services Bioequivalence study design, protocol design, study monitoring, IVIVC studies, BE failure investigation, and BCS-based bio-waiver strategies for generic pharmaceutical sponsors.
• Earth's Splendor In-house vitamin and supplement brand marketed by Contract Pharmacal Corp, sold via e-commerce direct-to-consumer from its website launched in 2023.

Quantifiable outcome

• No observations in last eight FDA inspections
• +3 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Earth's SplendorminorOthersCPC markets its own in-house vitamin and supplement brand, Earth's Splendor, which launched its e-commerce website in 2023. This represents CPC's consumer-facing brand extension.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Patheon (Thermo Fisher Scientific): Operates as part of Thermo Fisher's pharma services segment offering solid oral dose, sterile, and API CDMO services. Overlaps with CPC in solid-dose contract manufacturing while operating at significantly greater scale and breadth.
• Perrigo Company: Leading OTC and store-brand pharmaceutical manufacturer, directly comparable to CPC's retail private-label OTC/supplement work and also a customer-type of CPC's. Operates at much larger scale with broader product portfolio.
• Teva Pharmaceutical Industries: World's largest generic manufacturer with extensive solid-dose capacity and a growing CDMO/services arm. Competes with CPC on generic solid-dose contracts and retailer private-label programs.
• NBTY (Nestlé Health Science): Major dietary supplement and vitamin manufacturer; CPC's SVP Operations previously led global manufacturing at NBTY. Direct overlap in dietary supplement contract manufacturing and private-label capabilities.

Direct peers

• Lannett Company: Generic pharmaceutical manufacturer focused on solid oral dose products distributed through wholesalers and retailers, mirroring CPC's generic and OTC customer segments.
• Amneal Pharmaceuticals: US-based generic and specialty pharmaceutical manufacturer with solid-dose manufacturing and growing private-label OTC exposure. Direct overlap with CPC's solid-dose and store-brand offerings.
• Aurobindo Pharma: Vertically integrated generic manufacturer with significant US solid-dose capacity and CDMO-style services through its Aurolife subsidiary. Competes with CPC for generic and OTC solid-dose contracts.
• Catalent: One of the largest global CDMOs with extensive solid oral dose, softgel, and specialty manufacturing capabilities. Catalent competes directly with CPC for OTC, supplement, and pharma solid-dose contracts, though at meaningfully larger scale.
• Breckenridge Pharmaceutical: Generic pharmaceutical company with strong private-label and retailer focus. CPC's VP of Business Development joined from Breckenridge, and both target overlapping retail and OTC channels.

Emerging players

• Florida Pharmaceutical Products: Smaller specialty pharmaceutical manufacturer and CDMO in which CPC made a strategic investment in 2019. Comparable in dosage forms and customer types but at smaller scale than CPC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/contract-pharmacal-corp

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Contract Pharmacal Corp